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Resumen
Introducción: El mesilato de deferoxamina aumenta la transactivación alfa inducible por hipoxia del factor 1 al 
prevenir el estrés por oxígeno reactivo catalizado por hierro, por lo que puede usarse para mejorar la cicatrización 
de la úlcera diabética. Este estudio se llevó a cabo para desarrollar y estudiar las propiedades fisicoquímicas de 
nanopartículas lipídicas sólidas cargadas con deferoxamina tópica.
Método: Se prepararon nanopartículas de lípidos sólidos utilizando la técnica de homogeneización en frío y un 
diseño factorial completo para evaluar el efecto del tipo de tensioactivo y la cantidad de lípidos. Se llevó a cabo 
la caracterización in vitro de las formulaciones, incluido el tamaño y la distribución de las partículas, el comporta-
miento térmico mediante calorimetría de barrido diferencial, la eficiencia de atrapamiento y el perfil de liberación.
Resultados: Los resultados mostraron un rango aceptable de tamaño de partícula (2,88-174 nm), una distribución 
de tamaño estrecha y un promedio del 60% para la eficacia de atrapamiento del fármaco, lo que es significativo para 
un fármaco hidrófilo. Los resultados del estudio de liberación mostraron una liberación de ráfaga inicial seguida 
de una manera lenta y prolongada. Los resultados de la calorimetría diferencial de barrido también confirmaron 
los resultados obtenidos de las evaluaciones de carga y liberación. La mejor formulación que tenía un alto nivel de 
carga de fármaco y la menor tasa de liberación de fármaco contenía compritol y ácido oleico en una cantidad del 8% 
de la fórmula total, así como tween 80 y lecitina como una mezcla de tensioactivos.
Conclusiones: El estudio demostró que el mesilato de deferoxamina podría cargarse en nanopartículas de lípidos 
sólidos para administrar por vía tópica.
Palabras clave: Mesilato de deferoxamina; Nanopartículas de lípidos sólidos; Entrega de formulación tópica
Abstract
Introduction: Deferoxamine mesylate increases hypoxia inducible factor-1 alpha transactivation by preventing 
iron-catalyzed reactive oxygen stress, so it can be used to improve diabetic ulcer healing. This study was undertaken 
to develop and study physicochemical properties of topical deferoxamine-loaded solid lipid nanoparticles.
Method: Solid lipid nanoparticles were prepared using cold homogenization technique and full factorial design 
to evaluate the effect of surfactant type and amount of lipid. In-vitro characterization of formulations including 
particle size and distribution, thermal behavior using Differential Scanning Calorimetry, entrapment efficiency, and 
release profile were carried out.
Results: The results showed an acceptable range of particle size (2.88–174 nm), a narrow size distribution, and an 
average of 60% for drug entrapment efficiency which is significant for a hydrophilic drug. The results from release 
study showed an initial burst release followed by a slow and prolonged manner. Differential Scanning Calorimetry 
results also confirmed the results obtained from loading and release evaluations. The best formulation which had a 
high level of drug loading and the lowest drug release rate contained compritol and oleic acid in the amount of 8% 
of the total formula, as well as tween 80 and lecithin as a mixture of surfactants.
Conclusions: The study demonstrated deferoxamine could be loaded in solid lipid nanoparticles to deliver topi-
cally.
Keywords: Deferoxamine mesylate; Solid Lipid Nanoparticles; Topical formulation delivery
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Highlights
Deferoxamine can be topically used to improve diabetic ulcer healing due to its capability of iron-che-
lating and improving angiogenesis. Solid lipid nanoparticles as a novel drug delivery carrier was ap-
plied not only to protect the drug from environmental damaging factors, but also to provide a local 
high concentration and a sustained-release of the drug. In such a way the limitations of oral and injec-
tion routes of administration the drug will be eliminated.
Introduction
Diabetic foot ulcer is one of the most common problems occurred in diabetic patients, leading to sig-
nificant disability and reduced quality of life such as amputation. Various factors are involved in the 
pathogenesis and occurrence of diabetic foot ulcers.(1) Decreased neovascularization caused by im-
paired activity of the transcription factor hypoxia inducible factor-1 alpha (HIF-1α) is a major factor. 
Based on the pathogenesis, new methods are needed to effectively manage and treat diabetic wounds. 
Deferoxamine mesylate [DFO], a strong iron-chelating agent, increases HIF-1α transactivation by pre-
venting iron-catalyzed reactive oxygen stress(2), so it can be used to improve ulcer healing in diabetic 
people. It is also one of the rare medicines available at clinic used in iron poisoning to remove excess 
iron from the body and in thalassemia patients associated with the problem of iron cumulated in the 
body. Less than 15% of the drug is absorbed through the gastrointestinal tract, so it is used via injec-
tion.(3,4)
Unfortunately, DFO has two main problems limiting its clinical application in many cases. The first 
problem is the short plasma half-life (below 90 minutes) that makes it inevitable to be applied in re-
peated doses or in the form of continuous and long-time injection. Secondly, it may cause acute or 
chronic poisoning that the latter is more likely to occur due to the necessity of long-term application of 
the drug in thalassemia and similar patients.(5)
On the other hand, its oral dosage form has been studied in which some gastrointestinal side effects 
such as nausea, vomiting, and abdominal pains have occurred in one third of subjects. Skin rash is also 
one of the side effects in both injection and oral administrations.(6,7) Acute renal failure is the most im-
portant considerable side effect of this medicine. In addition, it can be used in diabetic foot ulcer since 
it is discovered that due to the raise of glucose inside cells, activation of destroying mechanisms, like 
the production of free radicals, takes place. On this occasion, iron ion as a cofactor, has an important 
role in the conversion of superoxide free radical to poisonous hydroxyl radical, so avoids the continua-
tion of destructive reactions and improves angiogenesis.(8,9)
Taking into account instances mentioned above, seems that by providing and applying topical DFO 
loaded in solid lipid nanoparticles [SLN], we can produce a high concentration of it on diabetic ulcers 
in order to both eliminate injection problems and avoid systemic side effects of the drug. Considering 
the role of skin lipids in the barrier system, lipid-based carriers such as solid lipid nanoparticles can 
exchange the skin lipid resulting in improving dermal penetration.(10)
Solid Lipid Nanoparticles, which were first mentioned in 1991, are colloidal lipid carriers, very much 
like nanoemulsions, but differing in lipid nature. SLNs are obtained from physiological-like lipids and 
surfactants which are GRAS (Generally Recognized As Safe), free of toxicity. SLNs have a number of ad-
vantages over traditional colloidal systems, such as physical stability, protection of the active substance 
against chemical degradation, controlled release of the active substance, biocompatibility, selective 
targeting, absence of organic solvents, and easy to scale up and sterilize.(11-13) Solid lipid nanoparticles 
are attractive not only in the pharmaceutical industries but also in cosmetics and food industries.(14-16)
SLNs combine the advantages and avoid the disadvantages of other colloidal carrier systems such as 
liposomes and polymer nanoparticles. They could prolong the residence time of the dosage form at the 
absorption site, consequently increasing bioavailability. Controlled drug delivery, enhanced bioavail-
ability of entrapped drugs and/or improved tissue distribution, good tolerability, and drug targeting 
have been attributed to SLN formulations.(17)
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Due to such capability of solid lipid nanoparticles in long-term keeping of drug on injured skin and 
avoiding application of medicine in the form of injection or edible medicine and consequent preven-
tion of attributed side effects, it was aimed to formulate DFO in the form of solid lipid nanoparticles and 
to study its physicochemical properties such as particle size and size distribution, entrapment efficien-
cy, profile release, thermal behavior. The main objective of this study was to entrap DFO in solid lipid 
nanoparticles and investigate the characteristics of drug loading and release. Such particles, due to 
their nature, will remain for a long time on the applied area and will provide a slow-released and long 
action. Then, it is aimed to optimize the best formulation of the drug to provide conditions for studying 
on diabetic ulcers in future studies.
Materials and methods
Deferoxamine mesylate powder was purchased from Tolid Daru company(IR Iran), tween 80, PG, oleic 
acid, cholesterol, lecithin were obtained from Merck (Germany), span 20 were purchased from Pouyesh 
Kimia Gostar (IR Iran), cellulose acetate membrane was purchased from Tooba company (IR Iran), and 
compritol® 888 ATO (glyceryl behenate) was a gift from Gattefosse Pharmaceuticals Company (France). 
All chemicals and solvents were of analytical grade. Fresh double-distilled water was used in the exper-
iments. Minitab16 software was used for experimental design and evaluation of the effect of variables 
on responses.
Assay of drug
For measurement, the drug loaded/released from formulations, a standard curve was plotted by pre-
paring 6 solutions in different concentrations of the drug in phosphate buffer, pH=7.4, using a UV-visi-
ble spectrophotometer (CE250, CECIL, England) at 220 nm wavelength.
Experimental Design
To evaluate the effect of type of surfactant and type/amount of lipid, full factorial experimental design 
was applied. Based on this, 16 formulations in triplicate were prepared. The independent variables 
included the percentage of total lipid phase (%L), Liquid lipid to Solid lipid ratio (LL/SL), type of surfac-
tant, and type of lipid.
Preparation of deferoxamine-loaded SLNs
SLNs were prepared using an emulsion-congealing technique by cold high-pressure homogenization. 
The lipid phase consisted of a liquid oil (oleic acid), a solid lipid (cholesterol or comperitol 888 ATO), 
and a surfactant (Tween 80 + Span 20,1:1, or lecithin); the aqueous phase composed of water and 50 
mg DFO. The amounts of lipids and surfactants were varied according to factorial design presented in 
Table 1. The oil phase was melted at 65ºC, added to the aqueous phase at the same temperature and 
mixed for 3 minutes at speed of 12000 rpm using a high-speed homogenizer (Heidolph, Germany) to 
obtain a clear medium. Afterward, the mixture was further treated with sonication (90 W for 2 min); the 
emulsion was then diluted and congealed by adding a mixture of 4:1 water-propylene glycol to reach a 
final volume of 50 ml. The final concentration of DFO was 1mg/ml according to some studies. Finally, 
the suspension was passed through a high-pressure homogenizer (Emulsiflex-C3, Avestin, Canada) for 
3 cycles (20 seconds for each cycle) at 1000-2000 bars.(18-20)
Table 1. Independent variables and their levels
Variable High level Low level
Lipid Cholesterol + oleic acid (90:10) Comperitol + oleic acid (90:10)
%L 90% 80%
Surfactant Tween 80 + Span 20 (1:1) Lecithin
LL/SL 20:80 10:90
%L: Percentage of total lipid phase, LL/SL: Liquid lipid to Solid lipid ratio
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Measurement of particle size
Particle size analyzer instrument (Malvern, Master SIZER 2000) was used to evaluate particle size and 
size distribution. Samples were diluted with a determined double-distilled water.
Determination of drug entrapment efficiency [EE%]
To do this, 5 ml of each formulation was centrifuged at 12000 rpm for 10 minutes. After separation the 
particles, they were precisely rinsed with water, and then the amount of unloaded drug was measured 
in the watery part at 220 nm wavelength. To calculate the entrapment efficiency, the following equa-
tion was applied:
Study of release profile of drug
Static Franz Diffusion Cell System was used to determine the profile of release of entrapped drug in 
nanoparticles. To do this, a predetermined weight of each formulation was put in the donor part of the 
diffusion cell. Phosphate buffer, pH 7.4, was used as the recipient phase. The donor and the recipient 
units were separated with cellulose acetate membrane having a cut-off of 10 kDa. The temperature and 
speed of stirring the recipient phase were adjusted on 37±0.5 °C and 200 rpm, respectively. Sampling 
was carried out by withdrawal of 2 ml from the recipient phase at time intervals of 0.5, 1, 2, 3, 5, 6, 7, 8, 
12, 24, 36, 48, and 72 hours after starting the procedure. After each sampling, 2 ml of phosphate buffer 
was immediately added into the recipient to remain the volume equable. The cumulative amount of 
released drug was plotted versus time to obtain the release profile.
Thermal Behavior of Nanoparticles
To study the thermal behavior of nanoparticles, Differential Scanning Calorimetry (METTLER TOLIDO, 
Switzerland) was used through two profiles including heating (from +10 to +120° C) and cooling (from 
+30 to -60° C). Phase transitional temperature and enthalpy were determined and analyzed for each 
formulation.
Statistical Methods
Each formulation was prepared in triplicate, so the total numbers of formulations were 48. To analyze 
data, the Two-Way Analysis of Variance statistical test (ANOVA) was used to compare characteristics of 
formulations. In addition, for the study of the relationship between variables and responses, concur-
rent multiple regression was carried out. P-value equal to or less than 0.05 was considered as signifi-
cant correlation in all experiments.
Results
Particle size
The particle size ranged from 2.88 to 174 nm for all formulations as shown in Figure 1.
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Figure 1. Particle size for all formulations
The results show that most particles are less than 100 nm, so the method used to prepare formula-
tions had been properly able to produce nanoparticles. However, it has been no significant correlation 
between variables and particle size. Furthermore, it was found the average of 0.344 for polydispersity 
index that indicates a narrow size distribution in all formulations regardless particle size.
Drug Entrapment Efficiency
Determination of drug loaded in nanoparticles was assessed for all formulations. Figure 2 shows the 
drug loading percentage of SLN formulations.
Figure 2. Percentage of drug loading for all formulations
As shown, except formulation No. 2, all other formulations had more than 53% of entrapment efficien-
cy. This means that the contents of formulations were effective on the loading of drug. The average 
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loading for all formulations was about 60% which is considerable for DFO as a hydrophilic drug. Anal-
ysis of regression between variables and %EE identifies a significant correlation between lipid content 
and drug loaded in particles (p=0.014). Changing the solid lipid from cholesterol to Compritol®, resulted 
in an increase in the loading percentage. Based on regression analysis, none of the other variables did 
significantly affect %EE (P>0.05). Compritol, Glyceryl behenate, a high melting point glyceride with a 
less-ordered crystal lattice, is appropriate for use in dosage forms as a lipid matrix to increase drug 
entrapment and to modify (sustain or delay) the release of active ingredients.(21) It is safe and useful for 
increasing consistency and thickness for topical formulations. On the other hand, the lowest loading 
belongs to formulation No. 2 and the highest one belongs to No. 13. The latter includes Compritol and 
the higher level of LL/SL ratio which agrees with many of reports. According to these reports, the incor-
poration of liquid oil into solid lipid nanoparticles leads to increase crystal disorder and consequently 
results in great failure in the lattice and leaves more space to house the drug.(22,23)
Drug release profile
The drug release profile from SLNs is dependent on the preparation temperature, composition of emul-
sifier, and percentage of oil, especially liquid one, incorporated in the lipid matrix.(23)
Since one of the objectives of this study was to provide a slow release formulation to prolong the effect, 
the two factors %R2h and %R72h were considered as indices for slow-release and sustained-release. 
The in vitro drug release profiles of SLN formulations consisted of an initial burst release followed by 
a sustained and slow release. The averages release after 2 and 72 hours were 15.06% and 55.54%, re-
spectively.
Analysis of regression showed that both indices %R2h and %R72h had a significant direct correlation 
with %L, lipid content, and surfactant type (P=0.001), but a significant indirect correlation with LL/
SL (P=0.001). Except for one, for all other formulations the average of %R2h was 20 percent and some 
of the formulations had released more than 60 percent of loaded drug after 48 and consequently 72 
hours. Such profile is appropriate for a formulation which had been purposed for prolonged drug deliv-
ery. Besides, considering the initial burst release and followed by sustained release from formulations, 
it could be said that the drug is incorporated homogeneously, partially loaded in shell, interfacial and 
lipid core.(24) This is in accordance with Ramteke K.H et al which reported the drug was homogeneously 
loaded in particles using cold homogenization technique.(18)
Figure 3 represents the cumulative percentage of drug released from all formulations after 2, 8, 48, and 
72 hours, graphically.
Figure 3. Profile of release drug from all formulations
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Differential Scanning Calorimetery
DSC gives data from thermal behavior including melting and recrystallization of the solid lipids in SLNs. 
Various lipids have different melting points and enthalpies. The crystallinity degree of nanoparticles 
decreases with increasing liquid lipid ratio in the particles.(23) The liquid oil existing in lipid matrix is the 
main factor lowering the crystallinity and increasing the less-ordered structure of SLNs.
Table 2 presents the DSC results for SLN formulations through both heating and cooling manners.
Table 2. DSC results of SLN formulations
Formulation ΔH Phase Transitional Temp.
No. Cooling Heating Cooling Heating
1 115.4 -471 -25 114
2 80.9 -709.3 -29 101
3 216.3 -132.72 -23 90
4 46.1 -584.2 -31 117
5 30.148 -224.1 -35 114
6 442 -425.28 -15 123
7 85.18 -872.2 -24 118
8 65.8 -616.07 -22 115
9 90.6 -656.8 -23 110
10 32.8 -264.78 -29 119
11 44.5 -578.23 -26 70
12 58.83 -580 -25 83
13 56.89 -420.7 -29 68
14 87.7 -451.1 -24 90
15 72.23 -541.13 -29 72
16 64.23 -870.4 -32 110
As shown in heating program, the phase transitional temperature of 68 °C, the lowest one, belongs to 
formulation No. 13 containing cholesterol and lower level of LL/SL ratio. The highest one, 123 °C, be-
longs to No. 6 which consisted of Compritol and the higher level of LL/SL ratio. This result is compati-
ble with loading results. According to Chia-Lang Fang and et al, the decline of enthalpy and reduction 
of the melting point of the lipids occur in the SLNs with smaller size, higher surface area and a greater 
number of emulsifiers.(23) Figure 4 represents 2 samples of DSC thermograms for formulation No. 8.
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Figure 4. DSC Thermograms of formulation No. 8: a. heating, b. cooling
Discussion
The present study was designed to prepare a topical formulation of deferoxamine based on solid lipid 
nanoparticles. Such formulation can be used on diabetic foot ulcers to improve angiogenesis by re-
moving iron ions and hence avoid the side effects of oral or repeated injectable deferoxamine as well as 
overcome the problem of short plasma half-life and poor bioavailability of the drug. Selection of SLNs 
for drug delivery was based on their ability to protect the drug from destructive environmental factors 
and provide sustained-release condition. Despite numerous benefits of SLNs, one of their disadvantag-
es may be the low loading capacity due to the crystalline structure of solid lipids. The use of oleic acid, 
as results showed, overcame the drawback because of its less-ordered structure. Comperitol, com-
pared to conventional solid lipids, has a higher melting point so that formulations containing Comperi-
tol released the drug in a sustained manner. According to many reports, the minimized particle size and 
narrow size distribution can be obtained by applying high pressure homogenization technique.(14,22) 
The particle size in the majority of formulations prepared at the present study was accordance with the 
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reports. On the other hand, the application of cold homogenization technique was according to Rainer 
et al study in which the cold method was suggested for hydrophilic drugs to avoid partitioning the 
drug between the melted lipid and water phase during the hot homogenization. Relative high loading 
of deferoxamine in all formulations confirmed the suggestion. During cold homogenization method 
propylene glycol helps particles be spherical so provide the highest surface areas required for better 
loading and release of drug. It also increases loading capacity by preventing the loss of hydrophilic 
drug due to partitioning the drug into the water phase.(12)
Conclusion
deferoxamine mesylate, as a strong chelating agent, is used to remove excess iron from the body in poi-
soning cases and thalassemia patients. Since it must be injected repeatedly, so its adverse effects are 
unavoidable. There are some reports in which the beneficial effects of this drug on diabetic ulcers have 
introduced when applied locally. On the other hand, administration the drug using conventional dos-
age forms cannot provide a slow-release condition to avoid repeated use. According to the purpose of 
the study and considering all the results obtained for different formulations, formulation No. 13, which 
has a high level of drug loading and the lowest drug release rate, can be introduced as the best formu-
lation. This formulation contained compritol and oleic acid in the amount of 8% of the total formula, 
as well as tween 80 and lecithin as a mixture of surfactants. This study showed that deferoxamine may 
be loaded in solid lipid nanoparticles to provide desired conditions. However, this requires evaluating 
drug-loaded SLNs in ex-vivo and in-vivo conditions to achieve other properties such as permeation 
capability through intact and ulcered skin.
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